These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 28694698

  • 1. Maintenance therapy in COPD: time to phase out ICS and switch to the new LAMA/LABA inhalers?
    Tariq SM, Thomas EC.
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1877-1882. PubMed ID: 28694698
    [Abstract] [Full Text] [Related]

  • 2. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis.
    Rodrigo GJ, Price D, Anzueto A, Singh D, Altman P, Bader G, Patalano F, Fogel R, Kostikas K.
    Int J Chron Obstruct Pulmon Dis; 2017; 12():907-922. PubMed ID: 28360514
    [Abstract] [Full Text] [Related]

  • 3. Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis.
    Oba Y, Keeney E, Ghatehorde N, Dias S.
    Cochrane Database Syst Rev; 2018 Dec 03; 12(12):CD012620. PubMed ID: 30521694
    [Abstract] [Full Text] [Related]

  • 4. Inhaled treatment of COPD: a Delphi consensus statement.
    Ninane V, Corhay JL, Germonpré P, Janssens W, Joos GF, Liistro G, Vincken W, Gurdain S, Vanvlasselaer E, Lehouck A.
    Int J Chron Obstruct Pulmon Dis; 2017 Dec 03; 12():793-801. PubMed ID: 28293106
    [Abstract] [Full Text] [Related]

  • 5. Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal.
    Vanfleteren L, Fabbri LM, Papi A, Petruzzelli S, Celli B.
    Int J Chron Obstruct Pulmon Dis; 2018 Dec 03; 13():3971-3981. PubMed ID: 30587953
    [Abstract] [Full Text] [Related]

  • 6. Role of Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist Therapy in Chronic Obstructive Pulmonary Disease.
    Petite SE.
    Ann Pharmacother; 2017 Aug 03; 51(8):696-705. PubMed ID: 28410560
    [Abstract] [Full Text] [Related]

  • 7. Inhaled corticosteroids with combination inhaled long-acting beta2-agonists and long-acting muscarinic antagonists for chronic obstructive pulmonary disease.
    van Geffen WH, Tan DJ, Walters JA, Walters EH.
    Cochrane Database Syst Rev; 2023 Dec 06; 12(12):CD011600. PubMed ID: 38054551
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study.
    Casas A, Montes de Oca M, Menezes AM, Wehrmeister FC, Lopez Varela MV, Mendoza L, Ramírez L, Miravitlles M.
    Int J Chron Obstruct Pulmon Dis; 2018 Dec 06; 13():1545-1556. PubMed ID: 29785104
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist (ICS/LAMA/LABA) Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis.
    Ferguson GT, Darken P, Ballal S, Siddiqui MK, Singh B, Attri S, Holmgren U, de Nigris E.
    Adv Ther; 2020 Jun 06; 37(6):2956-2975. PubMed ID: 32335859
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trials.
    Sethi S, Donohue JF, Ferguson GT, Barnes CN, Crater GD.
    Ther Adv Respir Dis; 2020 Jun 06; 14():1753466620905278. PubMed ID: 32106777
    [No Abstract] [Full Text] [Related]

  • 13. An Evaluation Of Single And Dual Long-Acting Bronchodilator Therapy As Effective Interventions In Maintenance Therapy-Naïve Patients With COPD.
    Singh D, D'Urzo AD, Donohue JF, Kerwin EM, Molins E, Chuecos F, Ribera A, Jarreta D.
    Int J Chron Obstruct Pulmon Dis; 2019 Jun 06; 14():2835-2848. PubMed ID: 31827323
    [Abstract] [Full Text] [Related]

  • 14. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD).
    Horita N, Goto A, Shibata Y, Ota E, Nakashima K, Nagai K, Kaneko T.
    Cochrane Database Syst Rev; 2017 Feb 10; 2(2):CD012066. PubMed ID: 28185242
    [Abstract] [Full Text] [Related]

  • 15. Once daily long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus placebo for chronic obstructive pulmonary disease.
    Maqsood U, Ho TN, Palmer K, Eccles FJ, Munavvar M, Wang R, Crossingham I, Evans DJ.
    Cochrane Database Syst Rev; 2019 Mar 06; 3(3):CD012930. PubMed ID: 30839102
    [Abstract] [Full Text] [Related]

  • 16. Long-acting muscarinic antagonist and long-acting β2-agonist combination for the treatment of maintenance therapy-naïve patients with chronic obstructive pulmonary disease: a narrative review.
    Buhl R, Miravitlles M, Anzueto A, Brunton S.
    Ther Adv Respir Dis; 2024 Mar 06; 18():17534666241279115. PubMed ID: 39352722
    [Abstract] [Full Text] [Related]

  • 17. A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy.
    Mapel D, Laliberté F, Roberts MH, Sama SR, Sundaresan D, Pilon D, Lefebvre P, Duh MS, Patel J.
    Int J Chron Obstruct Pulmon Dis; 2017 Mar 06; 12():1825-1836. PubMed ID: 28684905
    [Abstract] [Full Text] [Related]

  • 18. Comparative Effectiveness of Long-Acting Beta2 -Agonist Combined with a Long-Acting Muscarinic Antagonist or Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease.
    Samp JC, Joo MJ, Schumock GT, Calip GS, Pickard AS, Lee TA.
    Pharmacotherapy; 2017 Apr 06; 37(4):447-455. PubMed ID: 28226405
    [Abstract] [Full Text] [Related]

  • 19. Comparative Effects of LAMA-LABA-ICS vs LAMA-LABA for COPD: Cohort Study in Real-World Clinical Practice.
    Suissa S, Dell'Aniello S, Ernst P.
    Chest; 2020 Apr 06; 157(4):846-855. PubMed ID: 31759966
    [Abstract] [Full Text] [Related]

  • 20. The effects of single inhaler triple therapy vs single inhaler dual therapy or separate triple therapy for the management of chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized controlled trials.
    Lai CC, Chen CH, Lin CYH, Wang CY, Wang YH.
    Int J Chron Obstruct Pulmon Dis; 2019 Apr 06; 14():1539-1548. PubMed ID: 31371939
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.